Latanoprost / Netarsudil: 7 agencies, 2021–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused latanoprost / netarsudil: all 5 decisive outcomes across 5 agencies were positive or positive with restrictions.
The record spans 3.8 years, opening at AWMSG (Wales) on 24 May 2021 and running to 10 Feb 2025.
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
The file is active: 6 of 7 records date from 2023 or later.
3 distinct indication wordings are recorded for latanoprost / netarsudil by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess latanoprost / netarsudil, on 24 May 2021; SMC (Scotland) did not open a file until 10 Feb 2025 — a wide spread of 3.8 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 4 of 7 dated records fall in 2023 alone.
Restriction is doing real work here: 2 of 5 decisive outcomes narrowed latanoprost / netarsudil to a subgroup rather than accepting or refusing it outright, at SMC (Scotland) and TLV (Sweden).
7 of the 18 agencies in this archive hold a record for latanoprost / netarsudil.
The full ledger for latanoprost / netarsudil reads 3 recommended, 2 restricted, 1 no benefit and 1 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| SMC (Scotland) | 10 Feb 2025 | Reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension (OHT) for whom monotherapy with a prostaglandin… | accepted (restricted) | source |
| NICE (England) | 2 Oct 2024 | NICE TA1009 | recommended | source |
| ZIN (Netherlands) | 22 Nov 2023 | GVS-advies latanoprost/netarsudil (Roclanda®) voor de behandeling van glaucoom en hoge oogdruk | reimbursed (GVS) | source |
| TLV (Sweden) | 20 Nov 2023 | Roclanda ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| HAS (France) | 5 Jul 2023 | Listing (Transparency Committee) | SMR low · ASMR V | source |
2 further decisions for latanoprost / netarsudil, across 2 agencies, are not shown here. They link to 2 further source documents.
Related molecules
- latanoprost — same ATC class S01E — Ophthalmologicals
- bimatoprost — same ATC class S01E — Ophthalmologicals
- travoprost — same ATC class S01E — Ophthalmologicals
- dorzolamide / timolol — same ATC class S01E — Ophthalmologicals
- latanoprost / timolol — same ATC class S01E — Ophthalmologicals
- bimatoprost / timolol — same ATC class S01E — Ophthalmologicals
Coverage: 7 decisions for latanoprost / netarsudil from 7 agencies, 2021 to 2025. Data to 7 Sep 2026. ATC class S01E — Ophthalmologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.